Zobrazeno 1 - 1
of 1
pro vyhledávání: ''
Publikováno v:
Antibody Therapeutics
Background CD3-based bispecific T cell engagers (bsTCEs) are one of the most promising bispecific antibodies for effective cancer treatments. To elicit target-specific T cell-mediated cytotoxicity, these bsTCEs contain at least one binding unit direc